Kazmira Therapeutics, the company behind initiatives such as Kazmira Pharmacy and Cannabidiol API, today launched Cope Now, a telehealth platform to deliver a regulated clinical pathway for cannabidiol (CBD) care.
The launch comes shortly after Kazmira's announcement of its prescription-only CBD pharmacy, which it called the nation's first 503A pharmacy specializing in pure compounded CBD without any tetrahydrocannabinol (THC), the intoxicating component in hemp.
The Cope Now platform offers patients clinician-led telehealth consultations designed to deliver personalized evaluation for those seeking access to regulated, pharmacy dispensed prescription CBD. Clinical oversight for the platform will be provided by Arora Health, ensuring structured and supervised support for CBD therapy to patients in the U.S.
Kazmira Therapeutics co-founder and co-CEO Pulak Sharma said the goal is to give patients a clinical pathway to ultra-pure compounded CBD that previously was missing.
"The Cope Now platform provides a structured intake and evaluation process so care decisions are clinically driven, not consumer-directed," Sharma said. "On May 28th, patients can schedule telemedicine appointments for prescription cannabis care with a board-certified clinician after confirming their eligibility through the Cope Now telehealth platform," he said.
Patients who meet eligibility criteria can begin scheduling telehealth consultations with a licensed clinician through copenow.com starting May 28. The platform will initially launch for patients in Colorado, with expansion into additional states planned in the coming months.
